| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/31/2013 | DE102011108346A1 Verwendung von Hemmstoffen der TMPRSS2 als Arzneimittel Use of inhibitors of TMPRSS2 as drugs |
| 01/31/2013 | CA2846573A1 Progesterone antagonists |
| 01/31/2013 | CA2843433A1 Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
| 01/31/2013 | CA2843432A1 Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| 01/31/2013 | CA2843431A1 Sandalwood oil and its uses related to skin disorders |
| 01/31/2013 | CA2843359A1 Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer |
| 01/31/2013 | CA2843273A1 N,n-dialkylalkylenyl esters, compositions thereof, and methods for use thereof |
| 01/31/2013 | CA2843251A1 N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors |
| 01/31/2013 | CA2843245A1 N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors |
| 01/31/2013 | CA2843195A1 Heterocyclyl pyrimidine analogues as jak inhibitors |
| 01/31/2013 | CA2843109A1 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| 01/31/2013 | CA2843102A1 Bicyclic pyrimidone compounds |
| 01/31/2013 | CA2843037A1 Levomilnacipran drug for functional rehabilitation after an acute neurological stroke |
| 01/31/2013 | CA2843022A1 Substituted quinolines and their use as medicaments |
| 01/31/2013 | CA2842983A1 Substituted heterocyclic aza derivatives |
| 01/31/2013 | CA2842976A1 Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
| 01/31/2013 | CA2842965A1 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors |
| 01/31/2013 | CA2842916A1 Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands |
| 01/31/2013 | CA2842894A1 Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
| 01/31/2013 | CA2842877A1 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| 01/31/2013 | CA2842866A1 Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| 01/31/2013 | CA2842841A1 Spirocyclic molecules as protein kinase inhibitors |
| 01/31/2013 | CA2842838A1 9-aminomethyl substituted tetracycline compounds |
| 01/31/2013 | CA2842835A1 Production of dha and other lc-pufas in plants |
| 01/31/2013 | CA2842798A1 Recombinant virus products and methods for inhibition of expression of dux4 |
| 01/31/2013 | CA2842796A1 Tumor selective chemokine modulation |
| 01/31/2013 | CA2842779A1 Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| 01/31/2013 | CA2842777A1 Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
| 01/31/2013 | CA2842756A1 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| 01/31/2013 | CA2842753A1 Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
| 01/31/2013 | CA2842745A1 Compositions containing zinc salts and isothiocyanates for reduction of oral volatile sulfur compounds (vscs) |
| 01/31/2013 | CA2842730A1 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| 01/31/2013 | CA2842672A1 Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| 01/31/2013 | CA2842644A1 Animal ectoparasite-controlling agent and method for preventing or treating infection in animals caused by parasites by using the controlling agent |
| 01/31/2013 | CA2842580A1 Technique for cleaving out part of poly(a) chain and/or 3'-terminal sequence of mrna to inhibit translation reaction |
| 01/31/2013 | CA2842566A1 Pyrazoline derivatives and their use as selective androgen receptor modulators |
| 01/31/2013 | CA2842528A1 Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators |
| 01/31/2013 | CA2842524A1 Activators of class i histone deacetlyases (hdacs) and uses thereof |
| 01/31/2013 | CA2842508A1 Bis-indolic derivatives, their uses in particular as antibacterials |
| 01/31/2013 | CA2842501A1 Bis-indolic derivatives, a process for preparing the same and their uses as a drug |
| 01/31/2013 | CA2842443A1 Synthetic lethality and the treatment of cancer |
| 01/31/2013 | CA2842355A1 Pentamidine amidoxime acid esters as prodrugs and use thereof as drugs |
| 01/31/2013 | CA2842337A1 Methods and compositions for treatment of epithelial wounds |
| 01/31/2013 | CA2842304A1 Dabigatran-amidoxime acid esters as prodrugs and use thereof as pharmaceuticals |
| 01/31/2013 | CA2842106A1 Cysteine prodrugs |
| 01/31/2013 | CA2841967A1 A crystalline form of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
| 01/31/2013 | CA2841911A1 Substituted 3 - (thiazole - 4 - carbonyl) - or 3 - (thiazole - 2 - carbonyl) - aminopropionic acid derivatives and their use as pharmaceuticals |
| 01/31/2013 | CA2841905A1 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 01/31/2013 | CA2841882A1 Indazoles |
| 01/31/2013 | CA2841417A1 Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| 01/31/2013 | CA2841361A1 Composition |
| 01/31/2013 | CA2841237A1 Quinolinyl glucagon receptor modulators |
| 01/31/2013 | CA2840029A1 Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| 01/31/2013 | CA2839606A1 Indene derivatives for use in the treatment of inflammatory bowel disease |
| 01/31/2013 | CA2838640A1 Heterocyclic amide derivatives as p2x7 receptor antagonists |
| 01/31/2013 | CA2837732A1 Methylphenidate-prodrugs, processes of making and using the same |
| 01/31/2013 | CA2816207A1 Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis |
| 01/30/2013 | EP2551346A1 Aptamer for ngf and use thereof |
| 01/30/2013 | EP2551283A1 Anti-allergic agent |
| 01/30/2013 | EP2551270A2 Pyrazolopyrmidine derivatives for use as pi3 kinase antagonists |
| 01/30/2013 | EP2551266A1 2',2-dithiazol non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof |
| 01/30/2013 | EP2551262A1 Glutamate derivatives or salts thereof |
| 01/30/2013 | EP2551255A1 Cannabinoid quinone derivatives |
| 01/30/2013 | EP2550968A1 Non-surgical removal of localized fat accumulation with a bile salt in conjunction with an analgesic or anti-inflammatory agent |
| 01/30/2013 | EP2550967A1 Compressed chewing gum tablet comprising taste-masking agent |
| 01/30/2013 | EP2550966A1 Amidoxime carboxylic acid esters of dabigatran as prodrugs and their use as medicaments |
| 01/30/2013 | EP2550965A2 Ceramide derivatives for treating polycystic kidney disease |
| 01/30/2013 | EP2550964A1 Temsirolimus for use in the prevention and/or treatment of a delta 9-tetrahydrocannabinol-induced anxiety disorder |
| 01/30/2013 | EP2550963A1 Amidoxime carboxylic acid esters of pentamidine as prodrugs and their use as medicament |
| 01/30/2013 | EP2550962A2 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof |
| 01/30/2013 | EP2550959A1 Lisuride, terguride and derivatives of same for use in the prevention and/or treatment of fibrotic changes |
| 01/30/2013 | EP2550957A1 Effervescent formulations of vildagliptin |
| 01/30/2013 | EP2550361A1 Compositions and methods for treating neurological disorders |
| 01/30/2013 | EP2550360A1 Bivalent antisense oligonucleotides |
| 01/30/2013 | EP2550288A1 Compositions and methods for non-toxic delivery of antiprogestins |
| 01/30/2013 | EP2550285A1 Trioxacarcins and uses thereof |
| 01/30/2013 | EP2550275A1 Pyrrolo[2,l-c][l,4]benzodiazepine-benzothiazole or benzoxazole conjugates linked through piperazine moiety and process for the preparation thereof |
| 01/30/2013 | EP2550274A1 Pyrrolopyrazine derivatives and their use as jak and syk inhibitors |
| 01/30/2013 | EP2550273A2 Pyrrolopyrazine kinase inhibitors |
| 01/30/2013 | EP2550272A1 Pyrazolopyrazine kinase inhibitors |
| 01/30/2013 | EP2550267A1 Analogues for the treatment or prevention of flavivirus infections |
| 01/30/2013 | EP2550266A2 Heterocyclic compounds useful for kinase inhibition |
| 01/30/2013 | EP2550263A2 Compositions and methods for treatment of neurodegenerative disease |
| 01/30/2013 | EP2550258A2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| 01/30/2013 | EP2550257A1 Pharmaceutically active disubstituted triazine derivatives |
| 01/30/2013 | EP2550255A1 Imaging agents for detecting neurological disorders |
| 01/30/2013 | EP2550254A1 Cyclopentyl - and cycloheptylpyrazoles as fxr modulators |
| 01/30/2013 | EP2550252A1 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds |
| 01/30/2013 | EP2550020A2 Reverse micelle microemulsion comprising metal ions and use thereof |
| 01/30/2013 | EP2550004A1 Heparan sulfate replacement therapy |
| 01/30/2013 | EP2550003A1 Pharmaceutical compositions containing substituted 6-deoxy-6-sulfanylcyclodextrin |
| 01/30/2013 | EP2550002A1 Rna interference in dermal and fibrotic indications |
| 01/30/2013 | EP2550001A1 Rna interference in ocular indications |
| 01/30/2013 | EP2550000A1 Reduced size self-delivering rnai compounds |
| 01/30/2013 | EP2549999A1 Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates |
| 01/30/2013 | EP2549998A1 Pharmaceutical composition comprising a pyrimidineone derivative |
| 01/30/2013 | EP2549997A2 Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same |
| 01/30/2013 | EP2549996A1 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amin0-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal |
| 01/30/2013 | EP2549995A2 Use of anatabine to treat inflammation and methods of synthesizing anatabine |
| 01/30/2013 | EP2549994A1 Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells |